A

Apnimed

APMDRecent IPO

Apnimed, Inc. · Nasdaq · Sleep-medicine biotechnology · Report filing 2026/07/31 · SEC checked 2026-10-07

SEC
DAILY SEC UPDATE424B4 analysed from the latest filing

Apnimed priced its IPO at $16.00 per share, with 12.0 million shares offered and an FDA PDUFA goal date of February 28, 2027 for Oxnimbi.

One-minute decisionBASIC RESEARCHSource completeness · 84%

Newly listed — review valuation, deal quality and post-IPO supply before acting

Apnimed, Inc. began trading on 2026-07-31 at an IPO price of $16.00; the final prospectus and offer terms are linked to SEC EDGAR.

Where does the money go?—No estimate is substituted for missing offer terms.
Ownership and votingExisting holders~78.3%* economic · Not separately disclosed voting
Next disclosed checkpointFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility

Capital destination

—

No estimate is substituted for missing offer terms.

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗
Next checkFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility

Capital destination

—

No estimate is substituted for missing offer terms.

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriting syndicate
CONFIRMED
  1. 1BofA Securities, Inc.38.00%4,560,000 shares
  2. 2Evercore Group L.L.C.28.50%3,420,000 shares
  3. 3Cantor Fitzgerald & Co.26.00%3,120,000 shares
View all 4 institutions
  1. 4LifeSci Capital LLC7.50%900,000 shares
The complete final-prospectus syndicate and each disclosed purchase commitment are shown below.Allocation basis: Final base underwriting commitment: 12,000,000 shares. Percentages are calculated from the final prospectus table and rounded to two decimals. This is underwriting commitment, not fees or post-listing ownership.Source · 424B4 ↗

Fully diluted valuation bridge

StatusReference
Awaiting verificationSource ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · 424B4 ↗

Existing holders

~78.3%*

The estimate compares offered shares with the latest reported shares outstanding and is not a voting-control conclusion.

Latest available filing · 2026/07/31

Review the beneficial-ownership table and voting rights together

One disclosed holder; not a complete ownership distribution.Check the source · 424B4 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

Calendar dates from 2026-07-31

  1. First trading day12.000M IPO shares
Holder / event
Holder / eventTerm / dateConditions
First trading day2026-07-31 ~21.7%* · 12.000M IPO shares12.000M IPO shares
Basis and evidence
First trading day

First trading day · 12.000M IPO shares

Lock-up / shares eligible for future sale ↗

Financial quality and runway

StatusReference
Awaiting verificationSource ↗

Latest filing update

Loading saved filing update…

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

Potential impact
High
Monitor
First post-IPO filing and lock-up schedule
Document424B4✓ Verified against the SEC source · SEC source document
Filed2026/07/311 public filings identified
Research updated2026/07/31SEC EDGAR
Evidence coverage84%Final prospectus, offer price, listing date and headline financial evidence reconciled
Open filing ↗

What remains missing16% of the evidence set remains unresolved. This may affect unconfirmed pricing, valuation, dilution or supply conclusions; no missing term is estimated.

View the filing's actual first page
Apnimed, Inc. 424B4 first page
424B4 first pageFirst page from SEC EDGAR